Attending SCOPE 2024 in Orlando, Florida?
If you'll be attending, make sure you visit us at Booth #300 to learn more about our virtual Sample Inventory Management (vSIM) solution, powered by AI.
Know your schedule in advance? Let's set up some time to discuss your needs and provide a personalized demo.
Tell Me What I Don’t Know: AI-Enhanced Decisions in Biomarker-Informed Trials
Drug development teams make data-driven decisions, but these decisions can be impacted by disparate data sources, siloed technologies, and fragmented insights. Deploying generative artificial intelligence (GAI) in drug development disrupts the limits of human-structured queries. We demonstrate how conversational AI empowers users to extract sample and biomarker information at the speed of decisioning. Predictive features of GAI enable novel insights by proactively surfacing information instead of passively waiting for input.
Join Tobi Guennel, PhD, Senior Vice President Product & Chief Architect, for his presentation on Monday, February 12 at 12:20pm EST.
AI in Clinical Trials: Transformative or Just Hype?
Read the op-ed in Applied Clinical Trials by Tobi Guennel outlining how AI will speed up clinical trial execution as sponsors integrate AI-enabled technologies into their day-to-day workflows.
Ready for more information? Reach out.
Precision for Medicine is the first biomarker-driven clinical development organization supporting life sciences companies in the use of biomarkers essential to targeting patient treatments. Precision for Medicine is part of Precision Medicine Group, with 3,000 employees in 40 locations.
QUARTZBIO® and the PRECISION QUARTZBIO logo® are registered trademarks of Precision Medicine Group, LLC in the United States and/or other jurisdictions. All rights reserved. The names and logos of other companies and products appearing on the website may be trademarks or registered trademarks of such other companies.